{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:19:32Z","timestamp":1790223572964,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunotherapy has significantly advanced cancer treatment, enhancing overall survival in melanoma, lung cancer, triple-negative breast cancer and renal cell carcinoma. However, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including severe cutaneous toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aims to investigate the demographics, incidence, presentation, management and survival outcomes of patients experiencing European Society for Medical Oncology (ESMO) grade 3 and 4 cutaneous toxicities secondary to various ICI regimens across all solid tumour types at a single tertiary oncology centre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective observational study looked at 5042 adult oncology patients treated with ICIs for all solid tumours at The Royal Marsden NHS Foundation Trust over a 9-year period between April 2015 and March 2024. Patients managed with commonly used ICIs (pembrolizumab, nivolumab, ipilimumab, cemiplimab, avelumab and atezolizumab, and combinations) were included in the study population. A data cross-search of these patients and those supplied with moderately potent to very potent topical steroids was done, resulting in 619 patients. Electronic patient records for these 619 patients were manually examined to determine the number of patients meeting the criteria for grade 3 or 4 cutaneous toxicity as per the ESMO guidelines. In total, 88 patients met the criteria, and relevant data were manually extracted from these patients\u2019 records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 5042 patients receiving ICIs, 88 (1.7%) developed grade 3 or 4 cutaneous toxicity. The most common tumour types were melanoma (42%) and lung (17%), renal (14%) and breast cancer (13%). The most frequently observed grade 3 toxicities were maculopapular eruptions (31%) and erythema (19%), with all grade 4 cases (8%) presenting as toxic epidermal necrolysis. The ICIs most associated with these toxicities were pembrolizumab (36%) and combined ipilimumab\u2013nivolumab (35%). Management involved oral corticosteroids (45%), intravenous methylprednisolone (23%) and topical steroids (18%). Immunotherapy was discontinued in all grade 4 cases and 64% of grade 3 cases. The overall survival rate at the time of data collection with a median follow-up of 38\u2005months was 44%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Severe cutaneous toxicities can result in the discontinuation of ICI therapy. Early recognition of severe cutaneous toxicity is necessary to balance effective management of skin toxicity with continued cancer control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf173","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:49:39Z","timestamp":1744858179000},"page":"1812-1817","source":"Crossref","is-referenced-by-count":6,"title":["Grade 3 and grade 4 cutaneous toxicities in patients with multiple solid tumour types receiving checkpoint inhibitor therapy: an observational study. The experience of a single large specialist institution"],"prefix":"10.1093","volume":"50","author":[{"given":"Zaina","family":"Sharif","sequence":"first","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveena","family":"Idaikkadar","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Okines","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadza","family":"Tokaca","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Aguilar-Duran","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2025082212465585500_llaf173-B1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2025082212465585500_llaf173-B2","doi-asserted-by":"crossref","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"key":"2025082212465585500_llaf173-B3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1759-7714.15205","article-title":"Real-world survival outcomes of immunotherapy for advanced non-small cell lung cancer: a single-center retrospective review","volume":"15","author":"Punchhi","year":"2024","journal-title":"Thorac Cancer"},{"key":"2025082212465585500_llaf173-B4","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3390\/cancers12082329","article-title":"Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma","volume":"12","author":"Asher","year":"2020","journal-title":"Cancers"},{"key":"2025082212465585500_llaf173-B5","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers"},{"key":"2025082212465585500_llaf173-B6"},{"key":"2025082212465585500_llaf173-B7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2025082212465585500_llaf173-B8","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082212465585500_llaf173-B9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.6004\/jnccn.2022.7020","article-title":"The risk of opportunistic infections and the role of antibiotic prophylaxis in patients on checkpoint inhibitors requiring steroids","volume":"20","author":"Shah","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025082212465585500_llaf173-B10","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025082212465585500_llaf173-B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025082212465585500_llaf173-B12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082212465585500_llaf173-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2025082212465585500_llaf173-B14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025082212465585500_llaf173-B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025082212465585500_llaf173-B16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ced.14469","article-title":"Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution","volume":"46","author":"Edwards","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025082212465585500_llaf173-B17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CJI.0000000000000352","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis: a review of the literature","volume":"44","author":"Ho","year":"2021","journal-title":"J Immunother"},{"key":"2025082212465585500_llaf173-B18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2025082212465585500_llaf173-B19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"2025082212465585500_llaf173-B20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025082212465585500_llaf173-B21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025082212465585500_llaf173-B22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/annrheumdis-2022-eular.3118","article-title":"POS0889 Case series of patients with eosinophilic fasciitis secondary to immune checkpoint inhibitors therapy","volume":"81","author":"Huang","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025082212465585500_llaf173-B23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025082212465585500_llaf173-B24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/bjd\/ljae202","article-title":"Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors","volume":"191","author":"Yiu","year":"2025","journal-title":"Br J Dermatol"},{"key":"2025082212465585500_llaf173-B25","doi-asserted-by":"crossref","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"2025082212465585500_llaf173-B26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"2025082212465585500_llaf173-B27","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-\u00adrelated adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025082212465585500_llaf173-B28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025082212465585500_llaf173-B29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082212465585500_llaf173-B30","doi-asserted-by":"crossref","first-page":"e2246400","DOI":"10.1001\/jamanetworkopen.2022.46400","article-title":"Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma","volume":"5","author":"Akturk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025082212465585500_llaf173-B31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025082212465585500_llaf173-B32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-\u00adrelated adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082212465585500_llaf173-B33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clgc.2020.05.010","article-title":"Correlation between immune-related adverse event (IRAE) occurrence and clinical outcome in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study","volume":"18","author":"Vitale","year":"2020","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf173\/62942353\/llaf173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1812\/62942353\/llaf173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1812\/62942353\/llaf173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:07Z","timestamp":1755881227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1812\/8114929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf173","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,17]]}}}